Neuropathy — Clinical Documentation Guide (2026)

🔍 Definition

Neuropathy refers to functional disturbance or pathological change in the peripheral nervous system — encompassing a broad spectrum of disorders affecting sensory, motor, and/or autonomic nerve fibers. The term encompasses mononeuropathy (single-nerve involvement), mononeuropathy multiplex (multiple non-contiguous nerves), and polyneuropathy (diffuse, often length-dependent involvement of multiple nerves). Peripheral nerves may be damaged by metabolic insults, immune-mediated mechanisms, toxic exposures, hereditary defects, compressive/entrapment forces, ischemia, infiltration, or infection.

From a coding perspective, neuropathy is never acceptably documented as a single stand-alone diagnosis without clarifying the etiology, pattern, and fiber type when known. The FY2026 ICD-10-CM Official Guidelines require coders to reflect the underlying cause whenever a causal relationship is established — most critically for diabetic neuropathy, which must be coded using the "with" convention under ICD-10-CM Guideline Section I.A.15.

Clinically, neuropathy is divided into:

• Large-fiber neuropathy: Impairs proprioception, vibration sense, deep tendon reflexes; detected on nerve conduction velocity (NCV) studies.
• Small-fiber neuropathy (SFN): Affects pain and temperature fibers (Aδ and C fibers); NCV/EMG are typically normal; diagnosis requires skin punch biopsy for intraepidermal nerve fiber density (IENFD) or quantitative sensory testing.
• Autonomic neuropathy: Involves the autonomic nervous system; may cause orthostatic hypotension, gastroparesis, neurogenic bladder, sudomotor dysfunction.

🗂️ Alternative Terminology

Clinicians, patients, and referring providers use many terms to describe neuropathy. Coders and CDI specialists must recognize lay and clinical synonyms to query appropriately and assign the correct code.

🩺 Signs & Symptoms

Symptoms vary substantially by fiber type and distribution. Thorough documentation of the symptom constellation guides code specificity and supports medical necessity for electrodiagnostic studies.

Sensory Symptoms

• Numbness, tingling, or "pins and needles" (paresthesia) — typically distal/stocking-glove in polyneuropathy
• Burning pain, allodynia, hyperalgesia — common in small-fiber predominant neuropathy and CIDP
• Loss of proprioception and vibration sense → sensory ataxia, positive Romberg sign
• Loss of pain/temperature sensation (small fiber) → risk of unnoticed wounds

Motor Symptoms

• Distal muscle weakness (foot drop in peroneal neuropathy, wrist drop in radial neuropathy)
• Atrophy of intrinsic hand muscles (ulnar/median neuropathy)
• Hyporeflexia or areflexia (ankle jerks lost early in length-dependent polyneuropathy)
• Fasciculations in severe axonal loss

Autonomic Symptoms

• Orthostatic hypotension, dizziness on standing
• Gastroparesis, constipation or diarrhea, nausea
• Neurogenic bladder (hesitancy, retention, incontinence)
• Anhidrosis or gustatory sweating
• Sexual dysfunction; fixed heart rate (cardiovascular autonomic neuropathy)

Entrapment / Mononeuropathy-Specific

• Carpal tunnel: nocturnal hand paresthesias, thenar atrophy, positive Tinel/Phalen signs
• Ulnar neuropathy: ring/little finger numbness, intrinsic weakness, claw hand
• Peroneal neuropathy: foot drop, steppage gait
• Sciatic neuropathy: posterior thigh/leg pain, weakness of knee flexion and all distal muscles
• Meralgia paresthetica: anterolateral thigh burning/numbness, no motor deficit

🧭 Differential Diagnosis

Accurate code assignment requires distinguishing neuropathy type and etiology. The following differentials are commonly encountered in inpatient, outpatient, and post-acute settings.

📋 Clinical Indicators for Coders/CDI

The following indicators, when present in documentation, support specific neuropathy code assignment and justify diagnostic procedures, treatments, and higher resource utilization levels.

🦴 Anatomy & Pathophysiology

The peripheral nervous system (PNS) consists of all neural structures outside the brain and spinal cord: cranial nerves (III–XII), spinal nerve roots, dorsal root ganglia, peripheral nerve trunks, plexuses, and the autonomic nervous system. Peripheral nerves are composed of:

• Large myelinated fibers (Aα, Aβ): Motor function, proprioception, vibration, and light touch.
• Small myelinated fibers (Aδ): Sharp pain, temperature, and some autonomic fibers.
• Unmyelinated fibers (C fibers): Burning pain, temperature, and postganglionic autonomic fibers (sudomotor, vasomotor, cardiac).

Major Pathophysiological Mechanisms

• Axonal degeneration: Direct axon injury (metabolic, toxic, ischemic); length-dependent (longest fibers affected first); Wallerian degeneration; slow/incomplete recovery. Seen in diabetic, toxic, and nutritional neuropathies.
• Segmental demyelination: Myelin sheath breakdown; conduction slowing on NCS; can be immune-mediated (CIDP, GBS) or hereditary (CMT type 1). Remyelination possible with treatment.
• Mixed axonal-demyelinating: Most common pattern in chronic polyneuropathies; seen in CIDP, severe diabetic neuropathy.
• Compression/entrapment: Mechanical focal demyelination then axon loss at anatomical tunnels (carpal tunnel, cubital tunnel, tarsal tunnel, fibular head).
• Immune-mediated: Antibody-mediated (anti-ganglioside antibodies in GBS/MMN, anti-CNTN1 in CIDP variants); complement activation; T-cell infiltration.
• Metabolic: Hyperglycemia → advanced glycation end-products (AGEs), polyol pathway activation, oxidative stress, mitochondrial dysfunction → nerve ischemia and axon loss in diabetic neuropathy per ADA Standards of Care.
• Vasculitic: Nerve ischemia from epineurial vessel inflammation → mononeuropathy multiplex pattern; requires nerve biopsy for definitive diagnosis.

Anatomical Entrapment Sites

• Median nerve: carpal tunnel (wrist), pronator syndrome (forearm), anterior interosseous syndrome
• Ulnar nerve: cubital tunnel (elbow), Guyon's canal (wrist)
• Radial nerve: spiral groove (wrist drop), posterior interosseous nerve at radial tunnel
• Common peroneal (fibular) nerve: fibular head — most common lower limb entrapment
• Tibial nerve: tarsal tunnel (medial ankle)
• Lateral femoral cutaneous nerve: inguinal ligament → meralgia paresthetica

💊 Medication Impact / Treatment

Pharmacologic management of neuropathy varies substantially by etiology and must be reflected in documentation to support medical necessity and accurate HCC risk adjustment.

Pain / Symptom Management

• Gabapentinoids: Gabapentin (Neurontin), pregabalin (Lyrica) — first-line for painful neuropathy per AAN guidelines; supports documentation of "painful neuropathy"
• SNRIs: Duloxetine (Cymbalta) — FDA-approved for diabetic peripheral neuropathic pain; documents severity and treatment
• TCAs: Amitriptyline, nortriptyline — second-line; document pain level and response
• Topical agents: Capsaicin 8% patch (Qutenza) — CPT 64616 for application; used for focal neuropathic pain; HCPCS J0291 for capsaicin 8% patch
• Opioids: Third-line; document refractory nature and prior treatment failures
• Lidocaine patches: Topical; limited evidence; document as adjunct

Disease-Modifying / Etiology-Specific

• IVIG (Intravenous Immunoglobulin): Standard of care for GBS (acute), CIDP (maintenance), MMN; AAN Practice Advisory; HCPCS J1569 (Gammagard Liquid 500 mg) per infusion visit
• Plasma exchange (plasmapheresis): GBS, CIDP; documents severity — typically inpatient; MS-DRG 023–024
• Corticosteroids: Prednisone or IV methylprednisolone for CIDP; document diagnosis and response
• Subcutaneous immunoglobulin (SCIG): Home maintenance for CIDP; J1561 (Gamunex) or J1569
• Rituximab: Refractory CIDP, anti-MAG neuropathy, vasculitic neuropathy; J9310
• Vitamin B12 (cyanocobalamin): B12-deficiency neuropathy; J3420 (IM injection); document deficiency etiology (D51.0 pernicious anemia vs E53.8)
• Thiamine (B1): Alcoholic neuropathy co-treatment; document alcohol use disorder + nutritional deficiency
• Glycemic optimization: Primary modifier for diabetic neuropathy; document HbA1c trend, insulin/oral agents, and complication stabilization or progression

Chemotherapy-Induced Neuropathy (CIPN)

Document the specific offending agent (taxane, platinum, vinca alkaloid, bortezomib, thalidomide) to code G62.0 with an appropriate adverse effect T-code. Dose modification or discontinuation of chemotherapy due to neuropathy must be documented by the oncologist and reflected in coding for episode-of-care reporting. Per ASCO guidelines, duloxetine is the only agent with moderate evidence for CIPN pain relief.

Preview ends here. The full guide continues with FY2026 ICD-10-CM code sets, CPT surgical coding, MS-DRG mapping, reimbursement guidance, CDI query templates, and an audit checklist — all available to CCO Members.

← Back to All Clinical Documentation Guides